MedTrace Logo

Multiple Ascending Dose Study for LCB01-0371

NCT01842516 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2014-11-17

No results posted yet for this study

Summary

Primary

* To investigate the safety and tolerability of LCB01-0371 after a multiple oral dose
* To investigate the pharmacokinetic characteristics of LCB01-0371 after a multiple oral dose in healthy male subjects
* To investigate the safety of LCB01-0371 after a multiple oral dose in healthy male subjects

Conditions

  • Healthy

Interventions

DRUG

LCB01-0371 800mg

LCB0-0371 800mg

DRUG

LCB01-0371 1200mg

LCB01-0371 1200mg

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • LigaChem Biosciences, Inc.

    lead INDUSTRY

Principal Investigators

  • Kyun-Seop Bae, MD, PhD. · Asan Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-03-31
Primary Completion
2013-07-31
Completion
2013-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01842516 on ClinicalTrials.gov